Membranous nephropathy treatment standard
Nephrology Dialysis Transplantation · 28.02.2024 · 39 (3) · 403-413
DOI: 10.1093/ndt/gfad225 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 02.11.2023. Verfasst von Yeshwanter Radhakrishnan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 79 Literaturangaben. Gefördert von: Mayo Foundation.
Abstract (Originalsprache)
Membranous nephropathy (MN) is characterized by deposition of immune complexes leading to thickening of glomerular basement membranes. Over time, the understanding of MN has evolved, with the identification of specific autoantibodies against novel podocyte antigens and the unraveling of intricate pathogenic pathways. Although the anti-CD20 monoclonal antibody rituximab is favored as part of the initial therapy in MN, a subgroup of MN patients may be resistant to rituximab necessitating the use of alternative agents such as cytotoxic therapies. In addition, newer agents such as novel anti-CD20 monoclonal antibodies, therapies targeting the CD38-positive plasma cells and anti-complement therapy are being studied in patients who are resistant to traditional treatment strategies. This manuscript furnishes a review of the novel developments in the pathophysiology of MN including the identification of target antigens and current treatment standards for MN, concentrating on evidenced-based interventions designed to attain remission and to prevent disease progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
ORCID-Profile: Sanjeev Sethi, Fernando C Fervenza
Förderung
- Mayo Foundation
Zitieren
APA
Radhakrishnan, Y., Zand, L., Sethi, S., & Fervenza, F. C. (2024). Membranous nephropathy treatment standard. Nephrology Dialysis Transplantation, 39(3), 403-413. https://doi.org/10.1093/ndt/gfad225
Vancouver
Radhakrishnan Y, Zand L, Sethi S, Fervenza FC. Membranous nephropathy treatment standard. Nephrology Dialysis Transplantation. 2024;39(3):403-413. doi:10.1093/ndt/gfad225
BibTeX
@article{Radhakrishnan2024,
author = {Radhakrishnan, Yeshwanter and Zand, Ladan and Sethi, Sanjeev and Fervenza, Fernando C},
title = {Membranous nephropathy treatment standard},
journal = {Nephrology Dialysis Transplantation},
year = {2024},
volume = {39},
number = {3},
pages = {403--413},
doi = {10.1093/ndt/gfad225}
}
EUVIMED